Information About Actos
The Food and Drug Administration has warned that patients taking the diabetes drug Actos (pioglitazone) may face an increased risk of developing bladder cancer. Health officials in Europe have ordered Actos to be recalled due to this increased cancer risk.
Actos is a drug used to treat patients with diabetes by making the body more sensitive to insulin in order to increase blood sugar levels. Actos became the best-selling drug in a class of diabetes medications known as thiazolidinediones after the only other drug in its class—Avandia—was severely restricted from sale in the U.S. due to a link with heart attacks and other cardiovascular problems.
According to a safety review begun by the FDA in September 2010, patients who take Actos for more than one year face an increased risk of developing bladder cancer. Researchers have found that the increased risk of bladder cancer may be as high as 40% for patients who have taken Actos for an extended period.
Based on these findings, the FDA issued a warning for Actos in June 2011 about the bladder cancer risk associated with the drug. The agency warned patients to be alert for symptoms of bladder cancer, including blood or a red color in the urine, urgent need to go to the bathroom, pain while urinating, back pain or lower abdominal pain.
After researchers in France confirmed the link between Actos and bladder cancer, health officials in both France and Germany ordered a recall of the drug. So far, the FDA has not announced plans to recall Actos.
If you or a loved one used Actos and were diagnosed with bladder cancer—or have developed any symptoms of this disease—you may be eligible to file a lawsuit. For a free legal consultation, contact the lawyers at Hissey Kientz, LLP by calling toll-free at 1-866-275-4454, or by filling out the free case evaluation form located on this page.